Update on the management of systemic vasculitis: What did we learn in 2009?

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  Hellmich, Bernhard ^a  

^a Kreiskliniken Esslingen   (Germany)

Author keywords

ANCA; Cyclophosphamide; Rituximab; Treatment; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR7; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLUENZA VACCINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; PREDNISONE; RAPAMYCIN; RIBAVIRIN; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; BIOLOGICAL MARKER; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; MYCOPHENOLATE MOFETIL; PREDNISOLONE;

ANCA ASSOCIATED VASCULITIS; ANTICOAGULANT THERAPY; B LYMPHOCYTE; BRAIN ISCHEMIA; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GIANT CELL ARTERITIS; HEPATITIS C VIRUS ASSOCIATED VASCULITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA VACCINATION; ISCHEMIA; KIDNEY FAILURE; LEUKOPENIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WEGENER GRANULOMATOSIS; IMMUNOLOGY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CRYOGLOBULINEMIC VASCULITIS; DRUG FATALITY; LEUKOENCEPHALOPATHY; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NONHUMAN; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; SYSTEMIC VASCULITIS;

EID: 77954569432     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. JAYNE D: Treatment of ANCA-associated small-vessel vasculitis. APMlS 2009; 117 (Suppl. 127): 3-9.
2. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7. Epub 2008 Apr 15.
3. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-23. Epub 2008 Apr 15.
4. HELLMICH B, FLOSSMANN O, GROSS W et al.: EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis. Ann Rheum Dis 2007; 66: 605-17.
5. GUILPAIN P, DE MENTHON M, PAGNOUX C, SEROR R, MAHR A, COHEN P: A bird's eye review of the recent literature. Clin Exp Rheumatol 2009; 27 (Suppl. 52): S5-S9.
6. DE GROOT K, HARPER L, JAYNE DR et al.: Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
7. DE GROOT K, ADU D, SAVAGE C: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-2027.
8. JONES RB, FERRARO AJ, CHAUDHRY AN et al.: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-68.
9. LOVRIC S, ERDBRUEGGER U, KUMPERS P et al.: Rituximab as rescue therapy in antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24: 179-85. Epub 2008 Aug 6.
10. ARIES PM, HELLMICH B, BOTH M et al.: Lack of efficacy of Rituximab in Wegener's Granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8.
11. TAYLOR SR, SALAMA AD, JOSHI L, PUSEY CD, LIGHTMAN SL: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1540-7.
12. SEO P, SPECKS U, KEOGH KA: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35: 2017-23. Epub 2008 Aug 1.
13. MARTINEZ DEL PERO M, CHAUDHRY A, JONES RB, SIVASOTHY P, JANI P, JAYNE D: B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009; 34: 328-35.
14. JONES R, COHEN TERVAERT JW, HAUSER T et al.: Randomized trial of rituximab vs. cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS. APMIS 2009; 117 (S 127): 78 (Abstract).
15. STONE J, MERKEL PA, SEO P et al.: Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). Arthritis Rheum 2009; 62: (S1).
16. CARSON KR, EVENS AM, RICHEY EA et al.: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40. Epub 2009 Mar 5.
17. FLEISCHMANN RM: Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60: 3225-8.
18. FLOSSMANN O, BASLUND B, BRUCHFELD A et al.: Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009; 68: 1125-30. Epub 2008 Aug 19.
19. FLOSSMANN O, JAYNE DR: Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology 2009; 23: 23.
20. IATROU C, ZERBALA S, REVELA I et al.: Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol 2009; 72: 31-7.
21. HIEMSTRA T, WALSH M, DEGROOT K et al.: Randomized trial of mycophenolate mofetil vs. azathioprine for maintenance therapy in ANCA-associated vasculitis (IMPROVE). APMlS 2009; 117 (Suppl. 127): 77-8 (Abstract).
22. KOENING CL, HERNANDEZ-RODRIGUEZ J, MOLLOY ES, CLARK TM, HOFFMAN GS: Limited utility of rapamycin in severe, refractory Wegener's granulomatosis. J Rheumatol 2009; 36: 116-9.
23. LITTLE MA, NIGHTINGALE P, VERBURGH CA et al.: Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2009; 1:1.
24. LIONAKI S, HOGAN SL, JENNETTE CE et al.: The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 2009; 76: 644-51. Epub 2009 Jun 17.
25. KNIGHT A, ASKLING J, GRANATH F, SPAREN P, EKBORN A: Urinary bladder cancer in Wegener's granulomatosis, risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63: 1307-11.
26. HELLMICH B, KAUSCH I, DOEHN C, JOCHAM D, HOLL-ULRICH K, GROSS WL: Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 2004; 63: 1183-5.
27. FAURSCHOU M, MELLEMKJAER L, SORENSEN IJ, THOMSEN BS, DREYER L, BASLUND B: Cancer preceding Wegener's granulomatosis: a case-control study. Rheumatology 2009; 48: 421-4. Epub 2009 Feb 12.
28. MORGAN MD, TURNBULL J, SELAMET U et al.: Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009; 60: 3493-500.
29. ALLENBACH Y, SEROR R, PAGNOUX C, TEIXEIRA L, GUILPAIN P, GUILLEVIN L: High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68: 564-7. Epub 2008 Nov 17.
30. CHARLIER C, HENEGAR C, LAUNAY O et al.: Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009; 68: 658-63. Epub 2008 May 26.
31. HOLVAST A, STEGEMAN CA, BENNE CA et al.: Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009; 68: 873-8. Epub 2008 Jul 14.
32. MUKHTYAR C, LEE R, BROWN D et al.: Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-32. Epub 2008 Dec 3.
33. MERKEL PA, CUTHBERTSON DD, HELLMICH B et al.: Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009; 68: 103-6. Epub 2008 Jul 29.
34. CABRAL DA, URIBE AG, BENSELER S et al.: Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009; 60: 3413-24.
35. ABDULAHAD WH, KALLENBERG CG, LIMBURG PC, STEGEMAN CA: Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2830-8.
36. HAUBlTZ M, GOOD DM, WOYWODT A et al.: Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009; 8: 2296-307. Epub 2009 Jun 28.
37. TERRIER B, SAADOUN D, SENE D et al.: Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009; 60: 2531-40.
38. BLOCKMANS D, COUDYZER W, VANDERSCHUEREN S et al.: Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology 2008; 47: 1179-84. Epub 2008 May 31.
39. MARIE I, PROUX A, DUHAUT P et al.: Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine (Baltimore) 2009; 88: 182-92.
40. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, GOMEZ-ACEBO, et al.: Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88: 227-35.
41. SCHMIDT WA, KRAUSE A, SCHICKE B, KUCHENBECKER J, GROMNICA-IHLE E: Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology 2009; 48: 383-5. Epub 2009 Jan 29.
42. BERGER CT, WOLBERS M, MEYER P, DAIKELER T, HESS C: High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 2009; 48: 258-61. Epub 2009 Jan 7.
43. SALVARANI C, DELLA BELLA C, CIMINO L et al.: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 2009; 48: 250-3. Epub 2008 Dec 24.
44. LEE TJ, KIM KH, CHUN JK, KIM DS: Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008; 49: 714-8.
45. SON MB, GAUVREAU K, MA L et al.: Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124: 1-8.
46. LAU AC, DUONG TT, ITO S, YEUNG RS: Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009; 60: 2131-41.